Cognition Therapeutics, Inc. – NASDAQ:CGTX
Cognition Therapeutics stock price today
$1.66
+0.82
+97.62%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 17 hours
Cognition Therapeutics stock price monthly change
-57.58%
month
Cognition Therapeutics stock price quarterly change
-57.58%
quarter
Cognition Therapeutics stock price yearly change
-55.56%
year
Cognition Therapeutics key metrics
Market Cap | 25.14M |
Enterprise value | 415.94K |
P/E | -2.02 |
EV/Sales | N/A |
EV/EBITDA | -0.01 |
Price/Sales | N/A |
Price/Book | 1.02 |
PEG ratio | -0.02 |
EPS | -0.91 |
Revenue | N/A |
EBITDA | -40.50M |
Income | -28.76M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCognition Therapeutics stock price history
Cognition Therapeutics stock forecast
Cognition Therapeutics financial statements
| Jun 2023 | 0 | -4.72M | |
|---|---|---|---|
| Sep 2023 | 0 | -6.74M | |
| Dec 2023 | 372K | -8.14M | -2188.44% |
| Mar 2024 | 0 | -9.15M |
| Dec 2023 | 372K | -8.14M | -2188.44% |
|---|---|---|---|
| Mar 2024 | 0 | -9.15M | |
| Oct 2025 | 0 | -8.60M | |
| Dec 2025 | 0 | -8.77M |
Analysts Price target
Financials & Ratios estimates
| 2024-05-07 | -0.23 | -0.27 |
|---|
| Jun 2023 | 43960000 | 9.57M | 21.78% |
|---|---|---|---|
| Sep 2023 | 38772000 | 9.84M | 25.39% |
| Dec 2023 | 35163000 | 10.68M | 30.4% |
| Mar 2024 | 38851000 | 9.99M | 25.72% |
| Jun 2023 | -3.69M | -18K | 2.09M |
|---|---|---|---|
| Sep 2023 | -4.16M | -58K | -3K |
| Dec 2023 | -5.45M | -30K | 2.43M |
| Mar 2024 | -7.24M | 0 | 11.99M |
Cognition Therapeutics alternative data
| Aug 2023 | 22 |
|---|---|
| Sep 2023 | 22 |
| Oct 2023 | 22 |
| Nov 2023 | 22 |
| Dec 2023 | 22 |
| Jan 2024 | 22 |
| Feb 2024 | 22 |
| Mar 2024 | 22 |
| Apr 2024 | 22 |
| May 2024 | 25 |
| Jun 2024 | 25 |
| Jul 2024 | 25 |
Cognition Therapeutics other data
14.53%
-15.93%
of CGTX is owned by hedge funds
20
-14
3.43M
-3.57M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 5700 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | RICCIARDI LISA director, officer.. | Common Stock | 5,700 | $1.75 | $9,975 | ||
Purchase | RICHSTONE ELLEN B director | Common Stock | 10,000 | $2.66 | $26,550 | ||
Purchase | FLETCHER AARON G.L. director, 10 percent owner | Common Stock | 1,871 | $2.65 | $4,958 | ||
Purchase | FLETCHER AARON G.L. director, 10 percent owner | Common Stock | 12,220 | $2.65 | $32,383 | ||
Purchase | FLETCHER AARON G.L. director, 10 percent owner | Common Stock | 1,973 | $2.65 | $5,228 | ||
Purchase | KREIS LESLIE W. director, 10 percent owner | Common Stock | 1,871 | $2.65 | $4,958 | ||
Purchase | KREIS LESLIE W. director, 10 percent owner | Common Stock | 12,220 | $2.65 | $32,383 | ||
Purchase | KREIS LESLIE W. director, 10 percent owner | Common Stock | 1,973 | $2.65 | $5,228 | ||
Purchase | KREIS LESLIE W. director | Common Stock | 8,269 | $1.4 | $11,577 | ||
Purchase | KREIS LESLIE W. director | Common Stock | 54,009 | $1.4 | $75,613 |
| Quarter | Transcript |
|---|---|
| Q4 2023 26 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q2 2023 12 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q4 2022 23 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q4 2021 30 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Ms. Lisa Ricciardi (1960) Chief Executive Officer, Pres & Director | $428,170 |
| Mr. James Michael O'Brien (1966) Chief Financial Officer | $418,210 |
-
What's the price of Cognition Therapeutics stock today?
One share of Cognition Therapeutics stock can currently be purchased for approximately $1.66.
-
When is Cognition Therapeutics's next earnings date?
Unfortunately, Cognition Therapeutics's (CGTX) next earnings date is currently unknown.
-
Does Cognition Therapeutics pay dividends?
No, Cognition Therapeutics does not pay dividends.
-
How much money does Cognition Therapeutics make?
Cognition Therapeutics has a market capitalization of 25.14M. Cognition Therapeutics made a loss 25.79M US dollars in net income (profit) last year or -$0.27 on an earnings per share basis.
-
What is Cognition Therapeutics's stock symbol?
Cognition Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CGTX".
-
What is Cognition Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cognition Therapeutics?
Shares of Cognition Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cognition Therapeutics's key executives?
Cognition Therapeutics's management team includes the following people:
- Ms. Lisa Ricciardi Chief Executive Officer, Pres & Director(age: 65, pay: $428,170)
- Mr. James Michael O'Brien Chief Financial Officer(age: 59, pay: $418,210)
-
How many employees does Cognition Therapeutics have?
As Jul 2024, Cognition Therapeutics employs 25 workers, which is 14% more then previous quarter.
-
When Cognition Therapeutics went public?
Cognition Therapeutics, Inc. is publicly traded company for more then 3 years since IPO on 8 Oct 2021.
-
What is Cognition Therapeutics's official website?
The official website for Cognition Therapeutics is cogrx.com.
-
Where are Cognition Therapeutics's headquarters?
Cognition Therapeutics is headquartered at 2500 Westchester Avenue, Purchase, NY.
-
How can i contact Cognition Therapeutics?
Cognition Therapeutics's mailing address is 2500 Westchester Avenue, Purchase, NY and company can be reached via phone at +41 24812210.
Cognition Therapeutics company profile:
Cognition Therapeutics, Inc.
cogrx.comExchange:
NASDAQ
Full time employees:
25
Industry:
Biotechnology
Sector:
Healthcare
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
2500 Westchester Avenue
Purchase, NY 10577
Purchase, NY 10577
CIK: 0001455365
ISIN: US19243B1026
CUSIP: 19243B102
